Gunderson Dettmer represented client Myst Therapeutics, a biotechnology company focused on advancing novel T-cell therapies for solid tumors, in its acquisition by Turnstone Biologics.
Gunderson Dettmer represented client Globality, an AI-powered digital solution for sourcing strategic services, in its $138.3 million Series E financing round led by Sienna Capital.
Gunderson Dettmer represented client Cockroach Labs, an open-source database platform, in its $160 million Series E financing round led by Altimeter Capital Management.
Gunderson Dettmer represented client Gro Intelligence, an AI-powered insights company, in its $85 million Series B financing round co-led by Intel Africa and Africa Internet Ventures.
Gunderson Dettmer advised client Athlon Acquisition Corp. on its initial public offering of 24,000,000 shares at the price to the public of $10.00 per share.
Gunderson Dettmer represented client Genalyte, a leading diagnostics and analytics company, in its $50 million financing round led by Verily.
Gunderson Dettmer represented client Affinivax, a clinical stage biopharmaceutical company, in its $226 million Series C financing co-led by Rock Springs Capital and Foresite Capital.
Gunderson Dettmer represented clients Altimeter, D1, Coatue and Dragoneer in the $525 million Series D financing of Lacework, a cloud security startup.
Gunderson Dettmer represented client Xencor, a clinical-stage biopharmaceutical company, in its collaboration agreement with MD Anderson to develop novel CD3 bispecific antibody therapeutics for the potential treatment of patients with cancer.
Gunderson Dettmer represented clients Altimeter and Dragoneer as they co-led the $520 million Series H financing of Roblox, a global online platform bringing people together through play.
Gunderson Dettmer represented client Coatue as it co-led the $300 million Series D financing of Hinge Health, a patient-centered Digital Clinic for back and joint pain.
Gunderson Dettmer represented Dragoneer in increasing its investment in PointClickCare, a cloud-based healthcare software for the long-term and post-acute care market.
Gunderson Dettmer represented client WeRide, a Chinese startup developing autonomous vehicles, in its $200 million Series B financing round led by Yutong Group.
Gunderson Dettmer client Barkbox, Inc., a leading global omni-channel brand for dogs, announced its definitive merger agreement with Northern Star Acquisition Corporation, a publicly-traded special purpose acquisition company (SPAC).
Gunderson Dettmer represented client GoCardless, an online-payment platform, in its $95 million Series F financing led by Bain Capital Ventures.
Gunderson Dettmer advised client ContextLogic Inc. dba Wish on its initial public offering of 46,000,000 shares of Class A common stock at a price to the public of $24.00 per share for a total of approximately $1.1 billion in aggregate gross proceeds.
Gunderson Dettmer represented Sofinnova as it led the $55 million Series A financing of Atsena Therapeutics, a clinical-stage gene therapy company.
Gunderson Dettmer represented client Overland Pharma in its joint venture with Allogene Therapeutics forming new company, Allogene Overland Biopharm, a separate venture that will develop, manufacture and commercialize allogeneic CAR T (AlloCAR T™) therapies for patients with cancer in greater China, Taiwan, South Korea and Singapore.
Gunderson Dettmer represented client Poynt, a payments processing startup, in its $320 million acquisition by GoDaddy.
Gunderson Dettmer represented client Dubsmash, a lip-syncing video application, in its acquisition by Reddit.
Gunderson Dettmer represented client Overland Pharma in its joint venture with ADC Therapeutics forming new company, Overland ADCT BioPharma (CY) Limited, that will develop and commercialize four of ADC Therapeutics’ antibody drug conjugate (ADC) product candidates for difficult-to-treat hematologic and solid tumors in greater China and Singapore.
Gunderson Dettmer represented client Cityblock Health, a startup improving health care for low-income patients with complex medical needs, in its $160 million Series C financing led by General Catalyst.
Gunderson Dettmer represented client PepGen, a therapeutics company targeting severe neuromuscular diseases, in its $45 million Series A financing led by RA Capital Management.
Gunderson Dettmer represented client Squire, a startup that sells software to barbershops, in its $60 million Series C financing led by Iconiq Capital. The raise is $45 million in equity capital and $15 million in debt financing.
Gunderson Dettmer represented client Xencor, Inc., a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, in its research collaboration and license agreement with Janssen Biotech, Inc.
Gunderson Dettmer represented client Veran Medical Technologies, an interventional pulmonology device, in negotiating and entering into an acquisition agreement with Olympus.
Gunderson Dettmer represented client Trash, an AI-powered video editing app, in its acquisition by VSCO.
Gunderson Dettmer represented client Andreessen Horowitz, a venture capital firm that invests in seed to late-stage technology companies, in its closing of two new funds, Fund VII and Growth II, totaling $4.5 billion.
Gunderson Dettmer represented client Abacus.AI, a San Francisco startup that seeks to automate deep learning models for customers, in its $22M Series B financing led by Coatue.
Gunderson Dettmer represented client Instana, an applications performance management startup with a cloud native approach, in its acquisition by IBM.
- Page 1 of 12